Precision medicine partnership between Pharmanovia and closed-loop medicine




Medication optimization technology will be incorporated with antihypertensive drugs

Closed Loop Medicine, a biotechnology company, and Pharmanovia, a company that extends the lifecycle of established medicines, have announced that they are embarking on a global collaboration.

Initially, the collaboration will focus on promoting a combined drug and software version of antihypertensive therapy in the UK. This will be rolled out in phases globally before other treatments are added.

Under the terms of the agreement, Closed Loop Medicine’s proprietary “software as a medical device” dosing optimization technology will be incorporated with Pharmanovia’s antihypertensive drug. A dual approach is available under a single prescription.

Preliminary clinical trial results indicate that Closed Loop Medicine’s technology may provide critical dose-optimized drug therapy while improving blood pressure control and reducing side effects.

Meanwhile, the two companies intend to help patients and healthcare professionals manage high blood pressure by developing a new class of combination products for treating high blood pressure.

Pharmanovia Chief Executive Officer Dr. James Bart believes this partnership has the potential to make a positive difference. This allows us to enhance established medicines with transformative technologies and bring much-needed innovation to areas of large unmet need. “

“Together, we aim to provide a first-in-class product that combines regulated software and medicines with the goal of improving patient outcomes while ensuring that the healthcare system maintains adherence. and the ability to reduce costly hospital procedures through improved patient engagement.”

Dr. Hakim Yadi, Chief Executive Officer and Co-Founder of Closed Loop Medicine, said, “This pioneering partnership will add value to iconic medicines through the power of software integration, making them more effective for patients. It’s a great example of what you can do,” he recalled.

He concluded: “Through this co-development agreement, we will bring our intellectual property, insights and technical know-how in dose-optimized drug and software integration, along with Pharmanovia’s innovative business model to create a well-known and trusted It enables brands to be valued and positioned to drive precision medicine product solutions around the world.”

Hypertension remains the most common cause of preventable disease and premature death worldwide, affecting more than 1 in 4 men and 1 in 5 women. The NHS alone now costs over £2.1 billion each year.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *